Literature DB >> 18226742

Pharmacoepidemiology and "in silico" drug evaluation: is there common ground?

Til Stürmer1, Kenneth J Rothman, Jerry Avorn.   

Abstract

Mesh:

Year:  2008        PMID: 18226742      PMCID: PMC2255561          DOI: 10.1016/j.jclinepi.2007.07.006

Source DB:  PubMed          Journal:  J Clin Epidemiol        ISSN: 0895-4356            Impact factor:   6.437


× No keyword cloud information.
  10 in total

Review 1.  Models for profiling the potential QT prolongation risk of drugs.

Authors:  Adam L Muzikant; R Christian Penland
Journal:  Curr Opin Drug Discov Devel       Date:  2002-01

2.  The marketplace can't give us the drug safety data we need.

Authors:  Jerry Avorn
Journal:  MedGenMed       Date:  2007-02-09

3.  Effect of concomitant use of benzodiazepines and other drugs on the risk of injury in a veterans population.

Authors:  Dustin D French; Thomas N Chirikos; Andrea Spehar; Robert Campbell; Heidi Means; Tatjana Bulat
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

4.  Insights into different results from different causal contrasts in the presence of effect-measure modification.

Authors:  Til Stürmer; Kenneth J Rothman; Robert J Glynn
Journal:  Pharmacoepidemiol Drug Saf       Date:  2006-10       Impact factor: 2.890

5.  Performance of propensity score calibration--a simulation study.

Authors:  Til Stürmer; Sebastian Schneeweiss; Kenneth J Rothman; Jerry Avorn; Robert J Glynn
Journal:  Am J Epidemiol       Date:  2007-03-28       Impact factor: 4.897

6.  New insights on the relation between untreated and treated outcomes for a given therapy effect model is not necessarily linear.

Authors:  Jean-Pierre Boissel; Michel Cucherat; Patrice Nony; Sylvie Chabaud; François Gueyffier; James M Wright; Michel Lièvre; Alain Leizorovicz
Journal:  J Clin Epidemiol       Date:  2007-11-28       Impact factor: 6.437

7.  Modeling and simulation of cancer immunoprevention vaccine.

Authors:  F Pappalardo; P-L Lollini; F Castiglione; S Motta
Journal:  Bioinformatics       Date:  2005-04-07       Impact factor: 6.937

8.  Causes.

Authors:  K J Rothman
Journal:  Am J Epidemiol       Date:  1976-12       Impact factor: 4.897

9.  The importance of critically interpreting simulation studies.

Authors:  G Maldonado; S Greenland
Journal:  Epidemiology       Date:  1997-07       Impact factor: 4.822

10.  A strengthening programme for weak associations.

Authors:  K J Rothman; C Poole
Journal:  Int J Epidemiol       Date:  1988-12       Impact factor: 7.196

  10 in total
  1 in total

1.  Methods to examine the impact of compliance to osteoporosis pharmacotherapy on fracture risk: systematic review and recommendations.

Authors:  Milica Nikitovic; Daniel H Solomon; Suzanne M Cadarette
Journal:  Ther Adv Chronic Dis       Date:  2010-11-01       Impact factor: 5.091

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.